Search
for
Sort by
Research 781–810 of 1000+
- ALOPECIA: AN EXTENSIVE NARRATIVE REVIEW OF TYPES, CAUSES, AND MANAGEMENT STRATEGIES
- Pharmacotherapy of androgenetic alopecia – a literature review
- New Drugs: Eculizumab
- The post-finasteride syndrome: possible etiological mechanisms and symptoms
- Cyberspace Chat
- Skin infections among infants and parental awareness: Is there any relationship?
- US Preterm Births: “D” Is for Dismal
- An update on the use of 5alpha-reductase inhibitors
- Lipid-based nanoparticles for topical delivery of hair growth therapeutic molecules
- What is the best treatment for frontal fibrosing alopecia, and if and when should it be transplanted?
- Association of breast cancer in men with exposure to 5-α reductase inhibitors: A RADAR report.
- Androgenetic alopecia; drug safety and therapeutic strategies
- Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
- CLINICAL UPDATES IN HAIR
- Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness?
- Finasteride Use: Evaluation of Depression and Suicide Risk
- 한국인의 두피모발 특성과 남성형탈모증
- Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease
- ADVANCEMENTS IN TREATMENT STRATEGIES FOR ANDROGENETIC ALOPECIA: NOVEL THERAPIES AND FUTURE PERSPECTIVES
- Androgenetic alopecia: An update
- May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
- HPLC characterization, molecular docking, QSAR and molecular dynamics simulation of Alstonia boonei phytochemical analogs as potent 5-alpha reductase inhibitors
- 5α-Reductase underscores the development of pectoral fin breeding tubercles in zebrafish
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Th,-e mechanistic insights into the application of retinoids and possible adjunct therapeutic treatment to androgenic alopecia
- Dermatological care of gender‐diverse patients in Australia
- COVID-19 and androgenic status: testosterone or dihydrotestosterone have a pivotal role?
- Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
- OR09-5 Importance of Islet Intracrinology for Glucose-Stimulated Insulin Secretion (GSIS) in the Male